-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Centerville, Cincinnati, Cleveland, Columbus
-
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, Columbus
-
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
NCT05704361 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland
-
Care in Multiple Sclerosis (MS)
NCT07011914 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Central Vein Sign in Multiple Sclerosis Extension Study
NCT07424027 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
ESIS in Pediatric DRE
NCT05469373 ·
Phase: Not specified ·
Ages: 1 Year to 30 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281 ·
Phase: Phase 3 ·
Ages: 40 Years to 70 Years ·
Sex: All (male and female)
· Ohio: Centerville, Cincinnati, Cleveland, Columbus
-
Electrical Stimulation Exercise for Individuals With Lower Limb Paralysis
NCT07768761 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NCT05964829 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
NCT06529406 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·
Phase: Phase 2 ·
Ages: 1 Day to 6 Months ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland, Dayton
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
TSC Biosample Repository and Natural History Database
NCT05676099 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Columbus
-
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
NCT06160310 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: Female
· Ohio: Cincinnati
-
Understanding and Enhancing Human Health and Movement
NCT07738978 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland